<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01981161</url>
  </required_header>
  <id_info>
    <org_study_id>1235207</org_study_id>
    <nct_id>NCT01981161</nct_id>
  </id_info>
  <brief_title>Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis</brief_title>
  <acronym>BEST-MS</acronym>
  <official_title>Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Under the escalation treatment strategy when a patient displays breakthrough disease&#xD;
      parameters under first line therapy, MS physicians are allowed by the EMEA to switch for&#xD;
      Natalizumab (NTZ) or fingolimod (FGL). NTZ and FGL efficacy have been demonstrated by&#xD;
      randomized therapeutic trial. As both treatments have been tested versus placebo a common way&#xD;
      to compare them is to look at their respective annualized relapse risk ratio decrease.&#xD;
      Roughly NTZ decrease by 70% and FGL by 50%. Nevertheless it is a terrible comparison since&#xD;
      the placebo group had different behaviour in the 2 trials and the patients demographic&#xD;
      features at baseline are also different. Therefore, it is right now totally impossible to&#xD;
      compare these 2 drugs with a decent methodology. Only a head-to-head comparison could do it.&#xD;
      Unfortunately this head-to-head comparison is not available and will not probably be done&#xD;
      under the drug companies initiative. During the time of this study, we will perform a phase&#xD;
      IV, observational, prospective head-to-head comparison of NTZ versus FGL efficacy in 600&#xD;
      patients. Our primary end point will be disease free patients after 1 year of treatment.&#xD;
      Further, this trial will allow us to collect new biological samples, useful for a validation&#xD;
      our project main aim. Further these new samples will be obtained from 3 European countries,&#xD;
      which is a must if we want to generalize our conclusion obtained from a French cohort.&#xD;
      Cooperation at the European level is thus essential for the implementation of this project .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2013</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 20, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free patients</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>comparing the efficacy of Natalizumab with that of Fingolimod with regard to the annual incidence rate (comparison against the annual incidence rate criterion after 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">307</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Fingolimod</arm_group_label>
    <description>patients treated by Fingolimod will have biological samples and clinical data</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natalizumab</arm_group_label>
    <description>patients treated by Natalizumab will have biological samples and clinical data</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological samples and clinical data</intervention_name>
    <arm_group_label>Fingolimod</arm_group_label>
    <arm_group_label>Natalizumab</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      urine and blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Multiple sclerosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of relapsing-remitting MS in line with McDonald criteria;&#xD;
&#xD;
          -  patient needing to be treated with FGL or NTZ, either:&#xD;
&#xD;
               -  Patients who have not responded to complete and well-conducted treatment with&#xD;
                  beta interferon. The patients should have presented at least one relapse during&#xD;
                  the course of the previous year while they were receiving treatment, and should&#xD;
                  present at least 9 hyper-intense lesions within T2 on a cerebral MRI, or at least&#xD;
                  1 enhancing lesion following injection of Gadolinium; or&#xD;
&#xD;
               -  Patients presenting severe and rapidly developing relapsing-remitting multiple&#xD;
                  sclerosis, defined by 2 debilitating relapses or more during the course of one&#xD;
                  year, combined with 1 or more high-intensity lesion(s) following injection of&#xD;
                  Gadolinium on a cerebral MRI, or a significant increase in lesion load within T2&#xD;
                  compared to a recent prior MRI.&#xD;
&#xD;
          -  EDSS score between 0 and 6, not inclusive;&#xD;
&#xD;
          -  patient who give informed consent, and signed the consent form;&#xD;
&#xD;
          -  patient available for 12-month follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General exclusion criteria: The patient is subject to judicial protection, supervision&#xD;
             or guardianship, the patient is pregnant, is about to give birth, or is&#xD;
             breast-feeding, or there is an existing medical or major psychiatric condition that,&#xD;
             in the investigator's opinion, could represent a risk for the subject or could&#xD;
             compromise compliance with the study protocol.&#xD;
&#xD;
          -  Contraindication to the use of NTZ and FGL in line with the marketing authorisation:&#xD;
             for NTZ, the risk of tuberculosis assessed by means of intracutaneous reaction or&#xD;
             quantiferon dosage, for FGL, positive VZV serology and an absence of risk factors for&#xD;
             bradycardia and heart rate problems, and for both molecules, an absence of biological&#xD;
             signs suggesting immunodepression (negative HIV serology, normal CD3, CD4, CD8 and&#xD;
             CD19 levels, weight-adjusted dosage of immunoglobulin normal).&#xD;
&#xD;
          -  prior treatment with FGL or NTZ;&#xD;
&#xD;
          -  prior treatment with Mitoxantrone or Cyclophosphamide type immunosuppressants during&#xD;
             the 5 years before inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Brassat, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U H Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nimes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université de Muenter</name>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Vall D'Hebron</name>
      <address>
        <city>Barcelone</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>progressive multifocal leucoencephalopathy</keyword>
  <keyword>JC virus</keyword>
  <keyword>Zoster infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

